This document is a USPTO patent application (US20260083761A1) filed on September 8, 2023, by Public University Corporation Nagoya City University. The application describes a pharmaceutical composition, a neuronal migration promoter, and a method for treating brain diseases by using a neuraminidase inhibitor to promote the migration of neurons. The abstract highlights the potential of this technology for neurological treatments.

As this is a patent application, it does not impose immediate compliance obligations on regulated entities. However, companies involved in pharmaceutical research and development, particularly in the area of neuroscience and brain disease treatment, should monitor the progress of this patent application and related technologies. The assignee and inventors are listed as Public University Corporation Nagoya City University, Kazunobu Sawamoto, and Mami Matsumoto.